S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NYSEAMERICAN:STXS

Stereotaxis (STXS) Stock Price, News & Analysis

$2.51
+0.02 (+0.80%)
(As of 03/27/2024 ET)
Today's Range
$2.46
$2.55
50-Day Range
N/A
52-Week Range
$1.33
$3.29
Volume
105,367 shs
Average Volume
249,797 shs
Market Capitalization
$206.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Stereotaxis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
79.3% Upside
$4.50 Price Target
Short Interest
Healthy
1.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.23) to ($0.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.67 out of 5 stars

STXS stock logo

About Stereotaxis Stock (NYSEAMERICAN:STXS)

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

STXS Stock Price History

STXS Stock News Headlines

The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Recap: Stereotaxis Q4 Earnings
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Stereotaxis Reports 2023 Full Year Financial Results
Stereotaxis Q4 2023 Earnings Preview
Earnings Preview For Stereotaxis
Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)
Stereotaxis Inc STXS
Stereotaxis Inc (RJR1.F)
See More Headlines
Receive STXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2024
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:STXS
CIK
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.50
High Stock Price Target
$5.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+79.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-20,710,000.00
Pretax Margin
-77.37%

Debt

Sales & Book Value

Annual Sales
$26.77 million
Book Value
$0.20 per share

Miscellaneous

Free Float
66,188,000
Market Cap
$206.15 million
Optionable
Not Optionable
Beta
1.35
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

STXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Stereotaxis stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stereotaxis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STXS shares.
View STXS analyst ratings
or view top-rated stocks.

What is Stereotaxis' stock price target for 2024?

2 Wall Street research analysts have issued 12 month target prices for Stereotaxis' shares. Their STXS share price targets range from $4.00 to $5.00. On average, they predict the company's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 79.3% from the stock's current price.
View analysts price targets for STXS
or view top-rated stocks among Wall Street analysts.

How have STXS shares performed in 2024?

Stereotaxis' stock was trading at $2.87 on January 1st, 2024. Since then, STXS shares have decreased by 12.5% and is now trading at $2.51.
View the best growth stocks for 2024 here
.

How were Stereotaxis' earnings last quarter?

Stereotaxis, Inc. (NYSEAMERICAN:STXS) posted its earnings results on Monday, March, 4th. The company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). The firm earned $4.57 million during the quarter, compared to analyst estimates of $7.55 million. Stereotaxis had a negative trailing twelve-month return on equity of 103.37% and a negative net margin of 77.37%.

What guidance has Stereotaxis issued on next quarter's earnings?

Stereotaxis updated its first quarter 2024 earnings guidance on Monday, March, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.0 million-$7.0 million, compared to the consensus revenue estimate of $6.7 million.

Who are Stereotaxis' major shareholders?

Stereotaxis' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.00%), Vanguard Group Inc. (3.00%), Essex Investment Management Co. LLC (1.45%), Kovack Advisors Inc. (0.28%), Independent Advisor Alliance (0.21%) and Investors Research Corp (0.04%).
View institutional ownership trends
.

How do I buy shares of Stereotaxis?

Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:STXS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners